{
  "id": 3716977,
  "title": "CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial",
  "url": "https://urgent.news/2026/08/27/cd19-car-t-cell-therapy-for-treatment-refractory-seropositive",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-27T00:00:00.000Z",
  "source": {
    "name": "Nature Medicine",
    "slug": "nature-medicine",
    "url": "https://www.nature.com/articles/s41591-026-04603-3"
  },
  "original_language": "en",
  "account": null,
  "summary": "Nature Medicine, Published online: 27 August 2026; doi:10.1038/s41591-026-04603-3 In the phase 1 part of the ongoing phase 1/2 COMPARE trial, CD19 CAR T cell treatment of patients with severe, treatment-refractory rheumatoid arthritis was well tolerated with clinical improvement seen in all patients.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "GEN Biotechnology",
        "title": "CAR T-Cell Therapy Puts Severe Rheumatoid Arthritis Into Remission in First Clinical Trial",
        "url": "https://urgent.news/2026/08/28/car-t-cell-therapy-puts-severe-rheumatoid-arthritis-into-remission-in",
        "published": "2026-08-28T17:33:07.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}